Editing Mesothelioma Treatment Centers (section)

=== Immunotherapy Breakthroughs ===

{| style="width:100%; background:#cce5ff; border:1px solid #007bff; border-left:5px solid #007bff; border-radius:4px; margin:1em 0;"
|-
| style="padding:15px; color:#004085;" | '''ℹ️ Research Milestone:''' The CheckMate 743 follow-up demonstrates that nivolumab plus ipilimumab achieves '''28% durable response at three years'''—compared to 0% for chemotherapy alone—fundamentally transforming treatment goals from palliation to potential long-term disease control.
|}

The FDA's September 2024 approval of pembrolizumab with chemotherapy, based on KEYNOTE-483 results showing '''17.3 months median overall survival''', provides another first-line option demonstrating nearly three-fold improvement in response rates. This approval expands treatment options available at community oncology practices, not just specialized centers.<ref>[https://mesotheliomaattorney.com/mesothelioma/treatment/new/ New Mesothelioma Treatments], MesotheliomaAttorney.com</ref>

According to Rod De Llano of Danziger & De Llano, "Clinical trial participation represents both a treatment opportunity and documentation opportunity for our clients. The detailed medical records generated during trial participation often strengthen compensation claims by establishing clear causation links between asbestos exposure and disease development."<ref>[https://dandell.com/lawyers/rod-de-llano/ Rod De Llano Attorney Profile], Danziger & De Llano</ref>

----